Novartis AG (0K9E)
London Exchange · UK · prices in USD · close of 20 Oct 2026
Key indicators
| Last close | USD 153.56 |
|---|---|
| 52-week range | 118.60 – 166.02 |
| Return, 1 month / 3 months | +8.3% / −0.3% |
| Return, 1 year / 3 years | +19.4% / +75.6% |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 26.4% |
| Worst drawdown (1 year) | -16.9% |
| Average daily value traded | 0.87M USD |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novartis is a pharmaceutical company based in Switzerland that researches, develops and makes prescription medicines. Its products treat conditions in areas such as cancer, heart disease, immunology, neuroscience and eye care, and it also supplies generic drugs through its Sandoz business. Its customers are mainly hospitals, doctors, pharmacies and health systems in countries around the world, and it runs research and manufacturing sites internationally.
The shares are listed on the London Exchange in UK under the code 0K9E, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novartis AG (0K9E) trades on the London Exchange in UK. It last closed at USD 153.56 on 20 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 1,317 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 19.4% and over the last three months it fell 0.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 56 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.9% | ||
| From 52-week high | -7.1% | ||
| Momentum | 55 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.3% | ||
| 6-month return | 4.3% | ||
| 12-month return, skipping the last month | 10.2% | ||
| Stability (higher is calmer) | 77 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.9% | ||
| Liquidity | 51 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.87M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 54 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +7.6% |
|---|---|
| 1 month | +8.3% |
| 3 months | −0.3% |
| 6 months | +4.3% |
| 1 year | +19.4% |
| 3 years | +75.6% |
| 5 years | +109.1% |
Signals
| 50-day / 200-day average | 148.13 / 150.62 |
|---|---|
| Golden / death cross (60 days) | Death, 10 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.17 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 Mar 2026 | CHF 4.0172 |
| 12 Mar 2025 | CHF 3.2771 |
| 7 Mar 2024 | CHF 3.1986 |
| 9 Mar 2023 | CHF 2.2742 |
| 8 Mar 2022 | CHF 2.1614 |
| 4 Mar 2021 | CHF 2.0794 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.